Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Down 73.0% in June

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,344 shares, a decrease of 73.0% from the May 31st total of 4,982 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 4,313 shares, the short-interest ratio is presently 0.3 days.

Addex Therapeutics Price Performance

Shares of ADXN stock traded up $0.13 during mid-day trading on Friday, hitting $6.07. The company had a trading volume of 11,119 shares, compared to its average volume of 4,545. The stock’s 50 day moving average price is $6.66 and its 200-day moving average price is $7.12. Addex Therapeutics has a 52-week low of $5.41 and a 52-week high of $12.05. The company has a market capitalization of $7.47 million, a P/E ratio of -1.06 and a beta of 1.48.

Addex Therapeutics (NASDAQ:ADXN) last posted its earnings results on Thursday, June 25th. The company reported ($1.50) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Wednesday, April 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Addex Therapeutics presently has an average rating of “Sell”.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.